Loading...
•
Jul 04, 2021
Illumina Q2 2021 Earnings Report
Reported record revenue driven by clinical applications and research.
Key Takeaways
Illumina reported a strong second quarter with record revenue of $1,126 million, a 78% increase compared to the prior year period. The company's performance was driven by clinical applications, including oncology and genetic disease testing, as well as research. As a result, Illumina raised its fiscal year 2021 financial guidance.
Revenue of $1,126 million, a 78% increase compared to the prior year period
GAAP net income of $185 million, or $1.26 per diluted share
Non-GAAP net income of $276 million, or $1.87 per diluted share
Raised fiscal year 2021 revenue growth guidance to 32%-34%
Illumina
Illumina
Forward Guidance
For fiscal 2021, the company now expects year-over-year revenue growth in the range of 32% to 34%, GAAP earnings per diluted share of $4.69 to $4.89, and non-GAAP earnings per diluted share of $6.30 to $6.50.
Positive Outlook
- Year-over-year revenue growth in the range of 32% to 34%
- GAAP earnings per diluted share of $4.69 to $4.89
- Non-GAAP earnings per diluted share of $6.30 to $6.50